Your session is about to expire
← Back to Search
CPX-351 for Myelodysplastic Syndrome
Study Summary
This trial is testing a new way to give an existing leukemia drug, in the hopes of helping patients whose disease has not responded to other treatments.
- Myelodysplastic Syndrome
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 309 Patients • NCT01696084Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants have been recruited for this research endeavor?
"Correct. Clinicaltrials.gov data suggests that this clinical trial, initially posted on July 25th 2019, is presently admitting patients. A total of 25 individuals need to be admitted from a single site."
Are there vacancies within this research effort that participants can fill?
"Affirmative. The clinicaltrials.gov website supports that this medical study, which was initially uploaded on July 25th 2019, is actively seeking volunteers. In total, 25 subjects need to be enlisted from a single site."
Can you expound on the toxicity profile of CPX-351 for humans?
"Our team has assigned CPX-351 a safety rating of 2, as this is Phase 2 trial and while there is evidence in support of its security profile, none exists to confirm efficacy."
Has CPX-351 been tested in any other experiments of a similar nature?
"Currently, there are 260 clinical trials in progress exploring the efficacy of CPX-351. Of those, 65 have reached Phase 3 and numerous research sites can be found across 12348 different locations, with a heavy concentration around Bronx, New york."
Share this study with friends
Copy Link
Messenger